Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor
-
Published:2024-10
Issue:
Volume:140
Page:112728
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Huang Xiao,
Chen Linhua,
Liu Li,
Chen Hefen,
Gong Zhujun,
Lyu Jianbo,
Li Yao,
Jiang Qi,
Zeng Xiangyu,
Zhang Peng,
Zhou HongORCID
Reference52 articles.
1. Diagnosis of gastrointestinal stromal tumors: a consensus approach;CD;Hum. Pathol.,2002
2. Recent progress and challenges in the diagnosis and treatment of gastrointestinal stromal tumors;Nishida;Cancers (Basel),2021
3. Gastrointestinal stromal tumours: origin and molecular oncology;Corless;Nat. Rev. Cancer,2011
4. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [published correction appears in Lancet. 2009 Aug 8;374(9688):450];Dematteo;Lancet,2009
5. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology;Von Mehren;J. Natl. Compr. Canc. Netw.,2018